Soleus Capital Management, L.P. Beam Therapeutics Inc. Transaction History

Soleus Capital Management, L.P.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$53.73 - $82.16 $153,130 - $234,156	-2,850 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$68.02 - $99.06 $329,897 - $480,441	-4,850 Reduced 62.99%	2,850 $227,000
Q3 2021 Nov 15, 2021	SELL	$84.37 - $133.6 $1.21 Million - $1.92 Million	-14,400 Reduced 65.16%	7,700 $670,000
Q2 2021 Aug 16, 2021	BUY	$64.12 - $128.71 $1.42 Million - $2.84 Million	22,100 New	22,100 $2.84 Million

236

75.2M

438K

232K

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.78B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

Get notified when there are updates to the investment portfolio of Soleus Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Soleus Capital Management, L.P. with notifications on news.